title: Anticancer IGF1R classes take more knocks.
authors.forename: Malini
authors.initials: M
authors.lastname: Guha
mesh_terms: D000911:Antibodies, Monoclonal / Q000009:adverse effects / Q000494:pharmacology; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents / Q000009:adverse effects / Q000494:pharmacology*; D015415:Biomarkers / Q000378:metabolism; D015195:Drug Design; D004345:Drug Industry; D006801:Humans; D058990:Molecular Targeted Therapy; D009369:Neoplasms / Q000188:drug therapy* / Q000473:pathology; D011720:Pyrazoles / Q000009:adverse effects / Q000494:pharmacology; D017526:Receptor, IGF Type 1 / Q000037:antagonists & inhibitors*; D014227:Triazines / Q000009:adverse effects / Q000494:pharmacology
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; C545990:BMS 754807; D015415:Biomarkers; D011720:Pyrazoles; D014227:Triazines; C545764:ganitumab; D017526:Receptor, IGF Type 1